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Natural Killer Cells Activated by MHC Class ILow Targets
Prime Dendritic Cells to Induce
Protective CD8 T Cell Responses
Introduction
Activation of dendritic cells (DC) by conserved patho-
gen-associated molecular patterns (PAMP) induces cy-
totoxic CD8 T cells (CTL) that recognize peptides pre-
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sented on MHC class I molecules. These activated CTL1GSF-Institut fu¨r Molekulare Immunologie
can specifically recognize and eliminate pathogenic mi-81377 Munich
crobial agents (Ka¨gi et al., 1996; Medzhitov and Jane-Germany
way, 2002; Matzinger, 2002). Viruses and tumors try to2 Department of Dermatology
evade adaptive immune responses by reducing self-Eberhard Karls University Tu¨bingen
MHC class I molecules on the cell surface (Xu et al.,72076 Tu¨bingen
2001; Alcami and Koszinowski, 2000). Even though lossGermany
of MHC protects against CTL, it remains unclear whether3 Department of Dermatology and Allergology
this really reflects an escape mechanism, since MHCLudwig-Maximilians-University Munich
class I also acts as a ligand for killer inhibitory receptors80336 Munich
(KIR). Cells missing MHC class I molecules lose resis-Germany
tance to NK cells and become susceptible to NK cell-4 WHO Immunology Research and Training Center
mediated lysis (Lanier, 1998; Long, 1999; Ravetch andInstitute of Biochemistry
Lanier, 2000; Moretta et al., 2001).University of Lausanne
Experiments with NKG2D receptor ligand (NKG2DRL)Switzerland
expressing tumors unraveled that these NK cell-stimu-5 Max-von-Pettenkofer-Institut
lating ligands cannot only activate NKG2DR-expressingLudwig-Maximilians-Universita¨t Munich
NK cells but also CD8 T cells and can induce protective80337 Munich
CTL responses (Diefenbach et al. 2001, Hayakawa etGermany
al., 2002). However, data performed with either CD70-6 GSF-Institut fu¨r Klinische Molekularbiologie
or CD80-transfected tumors suggest a novel pathwayund Tumorgenetik
for the induction of protective T cell responses that is81377 Munich
both NK cell- and interferon- (IFN-) dependent (KellyGermany
et al., 2002a, 2002b). This hypothesis is supported by7 Institute of Immunology
in vitro data showing that activated NK cells can releaseLudwig-Maximilians-University Munich
inflammatory cytokines and stimulate DC through an80337 Munich
IFN--dependent signal cascade (Glas et al., 2000; Ho¨g-Germany
lund et al., 1997; Brown et al., 2001; Kelly et al., 2002a,
2002b; Piccioli et al., 2002; Gerosa et al., 2002; Ferlazzo
et al., 2002; Zitvogel, 2002). Thus, in vivo recognition of
MHC class Ilow targets by NK cells might not only resultSummary
in direct killing of these target cells. Recognition of MHC
class Ilow targets may also activate NK cells and enableConserved molecular patterns derived from patho-
them to prime DC for IL-12 production. These IL-12-genic microorganisms prime antigen-presenting den-
producing DC1 then acquire the capacity to induce pro-dritic cells (DC) to induce adaptive T cell responses.
tective CTL responses. Such interactions between in-In contrast, virus-infected or tumor cells that express
nate and adaptive immunity may be crucial for the induc-low levels of major histocompatibility complex (MHC)
tion of specific CTL responses that follow infection withclass I activate natural killer (NK) cells for direct killing.
cytomegalovirus (CMV) and other noncytopathic vi-It is unknown whether NK cell recognition of MHC
ruses, which rapidly inhibit surface expression of MHCclass Ilow targets can also induce adaptive T cell re-
class I molecules on the infected cells (Biron et al., 1999).sponses. Here, we show that MHC class Ilow targets
To test this hypothesis and to study the in vivo role ofinitiate a cascade of immune responses, starting with
CMV-induced MHC class I suppression independentlythe immediate activation of NK cells. The activated
from other viral evasion mechanisms, we transfectedNK cells then prime DC to produce IL-12 and to induce
various tumor cells with mouse CMV (mCMV)-derivedhighly protective CD8 T cell memory responses. There-
genes that inhibit MHC class I export without affectingfore, sensing of MHC class Ilow targets by NK cells can
the expression of costimulatory molecules. We showlink innate and adaptive immunity to induce protective
that MHC class Ilow target cells can rapidly activate NKT cell responses and may alarm the immune system
cells in vivo. These activated NK cells then initiated aduring early infection with noncytopathic viruses.
cascade that started with the IFN--dependent priming
of DC toward an IL-12-producing DC1-phenotype,
which, subsequently, induced strong, protective CD8*Correspondence: mocikat@gsf.de (R.M.), mrocken@med.uni-
tuebingen.de (M.R.) T cell responses.
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Figure 1. In Vitro Characterization of MHC
Class Ilow Tumor Cells
(A) MHC class I downregulation in m152-
transfected A20 cells (gray area), as detected
by FITC-labeled anti-H-2Dd mAb HB87. The
hatched area represents A20 wild-type tu-
mor, the white area the isotype control. When
compared to the parental cells, the remaining
H2Dd mean fluorescence intensity of the
transfectants used in the experiments was
12% for A20-m152, 23% for A20-m06, and
19% for CT26-m06, respectively. Cells trans-
fected with empty cassettes had normal MHC
class I expression. Reduced MHC class I ex-
pression by CMV gene-transfected cells was
verified prior to all experiments.
(B) Expression of H-2 and various other sur-
face molecules by m152-transfected A20
cells (filled bars) or by A20 wild-type tumors
(open bars). Isotype controls had a mean
fluorescence8. Representative results from
at least two experiments.
(C) Specific lysis of m152-transfected A20low
or A20 wild-type lymphoma by TCR-trans-
genic influenza hemaglutinin (HA)-specific
CTL. Tumors were pulsed overnight with 3H-
thymidine and HA peptide, and specific lysis
was determined using the JAM test as de-
scribed in the Experimental Procedures. Ex-
periments were performed in triplicates.
Results and Discussion of costimulatory molecules, including CD70, CD80, or
NKG2DRL (Figure 1B). Similarly, MHC class I was selec-
tively suppressed on the CT26 carcinoma. Cell linesInhibition of MHC Class I Expression by mCMV-
transfected with empty vector cassettes had normal ex-Derived Genes Establishes Immunogenicity
pression of MHC class I (not shown) and served asin Lymphoma or Carcinoma Cell Lines
negative controls. Importantly, MHC class Ilow mutantsGrowth or rejection of tumors is a rigorous read-out
were not lysed by CTL (Figure 1C) and stimulated neithersystem. Therefore, acceptance or rejection of tumor
IFN- production nor proliferation by CTL (not shown).cells that differ only by the degree of MHC class I expres-
Therefore, transfection of A20 or CT26 cell lines pre-sion should provide important information on the effects
vented MHC class I expression without inducing costi-of MHC class I suppression on the various cellular com-
mulatory molecules that promote direct T cell activationponents of the innate and adaptive immune system in
by the MHC class Ilow mutant tumor.vivo. We transfected the A20 lymphoma and the CT26
As predicted by the original studies of Ka¨rre and co-carcinoma cell line with mCMV-derived genes, either
workers (Ka¨rre et al., 1986), reduced MHC class I expres-m152 or m06, that prevent cell surface expression of
sion protected against immune recognition in vitro only.MHC class I-peptide complexes in two different ways.
In vivo, inhibition of MHC class I expression by eitherm152 blocks the export of MHC class I complexes from
m152 or m06 strongly reduced or even abolished thethe ER/cis-Golgi compartment (Krmpotic et al., 1999),
capacity of A20 or CT26 tumor cells to grow in normalwhile the m06 gene product targets MHC class I com-
BALB/c mice (Figure 2A). Parental tumors or tumorsplexes to lysosomes (Ziegler et al., 1997). m152- and
transfected with empty vectors grew rapidly and causedm06-transfected A20 cells expressed low levels of MHC
class I (Figure 1A) but normal levels of MHC class II and death within 30 to 40 days (Figure 2A). Rejection of MHC
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I was directly responsible for the NK-dependent rejec-
tion of the m152-transfected tumors.
NK Cells Activated by MHC Class Ilow Tumors Prime
DC to Produce IL-12 and to Stimulate CD8
T Cells In Vivo
In vitro activation of NK cells by MHC class Ilow targets
enables them to interact with DC (Gerosa et al., 2002;
Zitvogel, 2002). To test in vivo whether NK cells only kill
the MHC class Ilow tumor cells or whether this NK-tumor
cell interaction results in a more complex interaction
that also involves other immune cells, such as DC or
T cells, we isolated lymphoid cells various times after
intravenous injection of MHC class Ilow A20 lymphomas
from the lung, the site of the first tumor cell passage,
and the spleen. Already 4 hr after injection of MHC class
Ilow A20 lymphomas, IFN-, IL-12p40, and IL-12p35
mRNA were strongly expressed in the lung and in the
spleen. In order to determine the precise cellular origin
of the IFN- or IL-12 mRNA, we prepared 99% pure
populations of either NK, DC, or non-NK cells by fluores-
cence-activated cell sorting, using multicolor staining,
as described (Biedermann et al., 2001). At 4 hr, IFN-
mRNA and protein was exclusively expressed by NK
cells (Figure 3A and insert). No IFN-mRNA was detect-
able in the remaining pool of non-NK cells of either
spleen or lung (Figure 3A and data not shown). In sharp
contrast, IL-12p40 and IL-12p35 mRNA appeared only
in highly purified DC (Figure 3B and data not shown).
Virtually no or only very little IFN- mRNA, IL-12 mRNA,
or IFN- protein appeared in either population after in-
jection of the parental A20 lymphoma (Figures 3A and
3B and data not shown). After 1 day, IFN- or IL-12
mRNA expression had declined. But on day four, IFN-
mRNA was again strongly expressed in both organs
(Figure 3C). However, at this time IFN- mRNA was ex-
pressed by the CD3CD8 T cell population (Figure 3C).
IFN- mRNA was also translated, as we found IFN-
protein on the surface of freshly isolated CD3 T cells
(Figure 3C, insert). Moreover, CD8 T cells from the spleen
produced large amounts of IFN- either spontaneouslyFigure 2. Rejection of MHC Class Ilow Tumor Cells Requires NK Cells
(not shown) or after in vitro stimulation (not shown) when(A) Survival of BALB/c mice after injection of 106 A20 or 106 CT26
cells. Injected tumor cells were either controls or cells transfected isolated and cultured for 2 days in vitro. In agreement
with either the m152 gene (A20low-m152) or the m06 gene (A20low- with the mRNA data, only T cells derived from mice
m06 or CT26low-m06). Tumor cells transfected with empty vector primed with MHC class Ilow A20 lymphomas produced
cassettes showed identical growth kinetics as wild-type cells. IFN-. These data are best conceivable with the concept
(B) Survival of BALB/c mice or NK cell-depleted BALB/c mice after
that MHC class Ilow A20 lymphoma activated NK cellsinjection of A20low cells. NK cells were depleted using rabbit anti-
and these activated NK cells then primed the local DCasialo GM1 antibody.
(C) Survival of BALB/c mice after injection of m152-transfected A20 to stimulate CD8 T cells. To directly test this hypothesis,
cells, following the restoration of MHC class I expression by preincu- we deleted NK cells prior to the injection of MHC class
bation with 670 U/ml IFN-. Ilow A20 lymphomas and analyzed again IFN- and IL-12
mRNA in these three populations. NK depletion entirely
abrogated the early IFN- peak by NK cells (Figure 4A,
class Ilow tumors was strictly dependent on NK cells upper two lanes), IL-12 mRNA expression by DC (Figure
(Figure 2B) and, as predicted (Ho¨glund et al., 1997), most 4A, lower two lanes), and subsequently the IFN-mRNA
mice survived even when given 10-fold higher numbers expression by CD8 T cells (Figure 4B). Thus, deletion of
of MHC class Ilow tumor cells (not shown). Enhancement NK cells did not only abolish the resistance of mice
of MHC class I expression on m152-transfected tumors against MHC class Ilow tumors (Figure 2B), it also pre-
by IFN- pretreatment prior to injection restored their vented activation of either DC or T cells. Together, these
capacity to grow in immunocompetent mice (Figure 2C). data exclude that either DC or T cells recognized the
Since under most conditions IFN- rather enhances the MHC class Ilow A20 lymphoma and strongly suggest a
immunogenicity of tumors (Ikeda et al., 2002), this result cascade, where NK cells first primed DC to become an
IL-12-producing DC1. These DC1 then stimulated CD8supports the concept that the suppression of MHC class
Immunity
564
Figure 3. MHC Class Ilow Tumors Activate NK
Cells to Prime DC for IL-12 Production and
for the Induction of CD8 T Cell Responses
(A) IFN- mRNA expression by sorted NK
cells, DC, and non-NK cells from spleens 4
hr after injection of either A20 or A20low lym-
phoma cells. Some of the mice had received
anti-IFN- mAb 4 hr before tumor challenge.
The insert shows IFN- DC, NK, or T cells
in the spleen detected by an IFN- capture
assay and counterstained for CD11c, DX5,
and CD3 expression. The high amounts of
IFN-detected in mice treated with A20low and
anti-IFN- are reproducible and are due to
the enrichment of IFN- on the cell surface
after anti-IFN- mAb treatment.
(B) IL-12p40 mRNA expression by sorted
CD11c DC or non-DC from spleens 4 hr after
intravenous injection of either A20 or A20low
lymphoma cells. Some of the mice had re-
ceived anti-IFN- antibody 4 hr before tu-
mor challenge.
(C) IFN- mRNA expression in CD3CD8
T cells 4 days after injection of either A20
or A20low lymphoma cells. Some of the mice
received anti-IFN- mAb 4 days before injec-
tion of A20low lymphoma cells. The insert
shows percentages of IFN- DC, NK, or
T cells in the spleen detected by an IFN-
capture assay and counterstained for CD11c,
DX5, and CD3 expression. All panels show
one out of two similar experiments.
T cells. Yet the data cannot exclude that NK cells directly T cells that were specifically induced by the MHC class
Ilow A20 lymphoma (Figure 4C). To test whether this con-stimulated CD8 T cells through DC-independent mecha-
nisms. As in vitro data revealed that priming of DC by secutive activation of first NK cells and then DC1 was
really T cell independent and to exclude any direct ef-activated NK cells is IFN- dependent (Gerosa et al.,
2002; Zitvogel, 2002), we neutralized IFN- during the fects of A20low lymphoma on T cells, we injected A20low
cells into mice with severe combined immune deficiencyinjection of MHC class Ilow A20 lymphoma. Neutralizing
IFN- had no effect on IFN- mRNA or protein expres- (SCID). Only A20low clearly induced detectable IFN- pro-
duction by NK cells (about 5%), while the effect of A20sion by NK cells (Figure 3A and insert), but entirely abro-
gated activation of both DC (Figure 3B) and T cells (Fig- lymphoma cells was much weaker (data not shown). In
consequence, A20low cells induced a strong and IFN--ure 3C and insert), strongly supporting the concept that
the DC-T cell interactions induced the IFN--producing dependent increase in IL-12-producing DC1, while A20
lymphoma cells had only a weak effect (Figure 5A).CD8 T cells and not direct NK-T cell interactions.
To directly test the functional relevance of this postu-
lated NK-DC1-T cell axis, we blocked, further down- MHC Class Ilow Tumors Induce Protective CD8
T Cell Responsesstream, the action of DC-derived IL-12 with mAb as
described (Biedermann et al. 2001). Indeed, anti-IL-12 Ka¨rre et al. found that NK cells can directly reject MHC
class I-deficient tumors (Ka¨rre et al., 1986). The dataentirely prevented the activation of IFN--producing
DC-Dependent T Cell Priming with MHC I-Loss Variants
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Figure 4. T Cell Priming Is Dependent on NK
Cells and IL-12
(A) IFN- and HPRT expression by NK cells
(upper two lanes) or IL-12p40 and HPRT ex-
pression by DC (lower two lanes). Mice re-
ceived either A20 lymphoma or A20low lym-
phoma cells. In half of the mice, NK cells were
depleted 3 days before by rabbit anti-asialo
GM1 antibody. Four hours after intravenous
tumor cell injection, the indicated cell popula-
tion was positively sorted and mRNA was am-
plified and determined as described (Bieder-
mann et al., 2001). N.D., not detectable
because of efficient NK cell depletion (con-
firmed by FACS analysis).
(B) Four days after injection of either A20 or
A20low lymphoma cells, CD3CD8 T cells
were isolated and IFN- mRNA expression
was determined by quantitative RT-PCR. In
half of the animals, NK cells were depleted.
(C) Percentages of IFN-CD3 spleen cells
as determined by an IFN- capture assay
after treating mice either with A20, A20low, or
A20low  anti-IL-12 mAb.
above showed that injection of MHC class Ilow A20 lym- as CpG-DNA 1668 (Biron et al., 1999; Dokun et al., 2001).
To determine whether in vivo activated NK cells arephomas did not only activate NK cells but also primed
DC to stimulate CD8 T cells. To test the biological rele- more efficient in rejecting MHC class Ilow tumors, SCID
mice received CpG-DNA 1668 prior to injection of eithervance of this T cell stimulation in vivo, we next studied
MHC class Ilow A20 lymphomas in nude/nude mice. Sur- MHC class Ilow or wild-type tumors. Pretreatment with
CpG-DNA 1668 resulted in solid protection, but onlyprisingly, nude/nude mice were entirely unable to con-
trol MHC class Ilow A20 lymphomas. As MHC class Ilow against MHC class Ilow tumor cells, whereas parental
tumors grew normally (Figure 5C). Therefore, only acti-A20 lymphomas grew in nude/nude mice as rapidly as
wild-type tumors (Figure 5B), the data showed (1) that vated NK cells deleted MHC class Ilow tumors efficiently
in the absence of T cells.the MHC class Ilow tumors tested had no growth defect
and (2) that resting NK cells alone were not capable of The failure of nude/nude or unprimed SCID mice to
control MHC class Ilow tumor cells demonstrated thatcontrolling these MHC class Ilow tumors. NK cells can be
further activated and their functioning can be enhanced resting NK cells alone could not achieve tumor cell elimi-
nation and suggested that T cells contributed to theby IL-2, IL-12, or immunostimulatory DNA motifs, such
Immunity
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also showed that only BALB/c mice “primed” with 106
MHC Ilow tumors developed protective immunity, while
mice that received only 105 MHC class Ilow A20 cells
during the initial priming remained fully susceptible to
the wild-type tumor (Figure 6A). Therefore, recognition
of 106 MHC class Ilow A20 lymphoma cells by NK cells
was required to generate the innate signals that primed
for protective immunity. As 106 tumor cells provide a
stronger stimulus for NK cells than 105 tumor cells, it is
most likely that the 10-fold higher number of MHC class
Ilow A20 lymphoma cells also provided a stronger alarm
signal for DC.
To determine the relative contribution of CD4 and CD8
cells to the T cell-mediated protection induced by MHC
class Ilow tumor cells, we depleted either CD4 or CD8
T cells with mAb. Each treatment deleted more than
99% of the targeted population (not shown). Injection
of control mAb or depletion of CD4 cells did not affect
the resistance against MHC class Ilow tumors (Figure 6B).
In sharp contrast, depletion of CD8 entirely abrogated
protection against the MHC class Ilow tumor cells, as
did depletion of NK cells with either anti-asialo GM1
antibody or anti-IL-2R chain mAb (Figures 2B and 6B).
In vitro, MHC class Ilow A20 cells induced neither CTL-
mediated killing nor T cell stimulation (Figure 1C and
data not shown). As the rapid stimulation of CD8 T cells
was obviously essential for the rejection of MHC class
Ilow A20 cells in vivo, we tried to develop CD8 T cell
lines, in order to obtain functional proof for the in vivo
stimulation of T cells. Indeed, we easily derived IFN--
producing, A20-specific T cell lines from mice injected
with MHC class Ilow A20 cells (Figure 7A), but only rarely
from mice that had received the parental A20 lymphoma
or from A20low-injected mice that were depleted of NK
cells. To test the in vivo relevance of this fast generation
of A20-specific CTL responses by MHC class Ilow tumors,
we injected MHC class Ilow A20 lymphoma cells together
with a lethal dose of A20 wild-type tumor. Simultaneous
injection of parental A20 lymphomas and MHC class Ilow
A20 lymphomas protected 25% of BALB/c mice against
the otherwise lethal wild-type tumor load (not shown),
Figure 5. DC-Activation by MHC Class Ilow Tumors Is T Cell Indepen- directly showing that recognition of MHC class Ilow A20
dent, but Rejection of MHC Class Ilow Tumor Cells Is T Cell Dependent lymphomas by NK cells rapidly generated A20-specific
(A) Percentages of IL-12-producing DC as determined by intracellu- CTL responses that even protected mice against a si-
lar FACS staining of spleen cells from SCID mice after treatment multaneous challenge with the lethal wild-type A20 lym-
with either A20, A20low, or A20low  anti-IFN- mAb. phoma.
(B) Survival of BALB/c nude/nude mice injected with either A20 wild-
Following injection of MHC class Ilow A20 lymphoma,type cells or m152-transfected A20 MHC class Ilow cells.
NK cells linked innate and adaptive immunity and estab-(C) Survival of SCID mice after injection of either 106 m152-trans-
lished long-term protection against the parental tumorfected A20 MHC class Ilow cells or 106 A20 wild-type cells. Half of
the SCID mice had received 10 nMol CpG-DNA 1668 oligonucleotide in normal BALB/c but not in SCID mice. To test whether
on days –1 and 1 of the tumor cell transfer. this protection was based on T cell memory or other
mechanisms, such as priming for antibody-dependent
cytotoxicity, we primed mice with MHC class Ilow A20
control of MHC class Ilow tumors in normal BALB/c mice. lymphomas and deleted T cells after 3 months, directly
If T cells were involved in the rejection of MHC class Ilow prior to a second tumor challenge. As shown above,
tumors, MHC class Ilow A20 lymphomas should establish inoculation with MHC class Ilow A20 tumors established
long-lasting protective immunity against the parental protective tumor immunity in BALB/c mice (Figure 6A).
tumors in BALB/c mice, but not in T cell-deficient SCID However, when T cells were deleted directly prior to the
mice. To test this, we injected MHC class Ilow A20 lym- challenge with A20 lymphoma, all mice died within 30
phoma cells either into BALB/c mice or into SCID mice days (Figure 7B). Thus, activation of NK cells with MHC
pretreated with CpG-DNA 1668. Three months later, we class Ilow A20 lymphomas initiated a cascade that started
challenged the surviving mice with a lethal dose of pa- with the priming of DC to become an IL-12-producing
rental A20 lymphoma. T cell-bearing BALB/c mice were DC1 phenotype and ultimately resulted in a CD8-depen-
protected while all SCID mice succumbed to the second dent T cell memory response that even protected
against the parental A20 lymphoma.tumor challenge (Figure 6A). Notably, these experiments
DC-Dependent T Cell Priming with MHC I-Loss Variants
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Figure 6. NK Cell-Induced Activation of DC
Establishes Long-Lasting Memory
(A) Long-term memory induced by NK cell-
mediated rejection of A20low variants. BALB/c
mice were primed with either 105 or 106 of
MHC class Ilow A20 cells or remained un-
primed. A fourth group of SCID mice was
primed with 10 nMol CpG-DNA and106 MHC
class Ilow A20 cells. On day 100, mice re-
ceived 106 A20 wild-type tumor cells and sur-
vival was monitored.
(B) Rejection of A20low lymphoma cells in
BALB/c mice requires NK and CD8 T cells.
BALB/c mice were depleted of the indicated
cell populations with mAb (CD8 cells with
RmCD8-2, CD4 cells with RmCD4-2, NK cells
with anti-IL-2 receptor  chain TM-1) 3 days
prior to the injection of 106 A20low lym-
phoma cells.
Concluding Remarks interactions occurred also in response to MHC class Ilow
cells, even though we did not address this point. These
DC1 cells had the capacity to recruit and activate naiveIt is currently assumed that recognition of either PAMPs
or “missing self” results in two distinct immune re- T cells through IL-12-dependent signals and to induce
protective CTL responses in vivo. Even though activa-sponses against microbial pathogens. PAMPs prime DC
and possibly other antigen-presenting cells to express tion of NK cells and induction of DC1 was entirely T cell
independent, we cannot exclude that IFN--producingcytokines and costimulatory molecules that induce
adaptive immune responses (Ka¨gi et al., 1996; Medzhi- CD8 T cells appearing around day 4 further enhanced
the establishment of protective immunity. This cross-tov and Janeway, 2002; Matzinger, 2002). In contrast,
NK cells directly lyse cells infected with viruses that priming, that follows the classical T cell activation path-
way, is fundamentally different from tumor immunity es-inhibit MHC class I expression during primary infection
(Medzhitov and Janeway, 2002; Matzinger, 2002; Lanier, tablished by stimulation through ligands of NKG2DR,
where NKG2DR-NKG2DRL interactions directly stimu-1998; Long, 1999; Ravetch and Lanier, 2000; Moretta et
al., 2001). More recent data suggest that, in addition, late CD8 T cells (Diefenbach et al. 2001; Hayakawa et
al., 2002; Zitvogel, 2002). Importantly, NK cells inducedNKG2DR-NKG2DRL interactions are capable to directly
stimulate naive CD8 T cells and to induce T cell memory CTL only when activated by large numbers of MHC class
Ilow cells. This threshold may explain why noncytopathic(Diefenbach et al. 2001; Hayakawa et al., 2002).
The data reported here show a novel pathway leading viruses that rapidly inhibit self-MHC expression in large
numbers of cells during primary infection induce strongto adaptive immune responses. Activation of NK cells
is dependent on activating receptors that are normally CTL responses, whereas tumors that slowly and pro-
gressively lose self-MHC remain largely ignored by thefunctionally silenced by MHC-recognizing KIR (Lanier,
1998; Long, 1999; Ravetch and Lanier, 2000; Moretta et adaptive immune system. Thus, sensing of missing self
by NK cells or immune activation by PAMP are twoal., 2001). Here, we demonstrate that activation of NK
cells by missing self can functionally link innate with alternative, innate pathways leading to the initiation of
adaptive immune responses.adaptive immune responses, through NK cell-depen-
dent priming of DC. Sudden appearance of MHC class
Ilow tumor cells resulted in rapid activation of IFN--pro- Experimental Procedures
ducing NK cells. Activation of NK cells was needed to
Generation and In Vitro Characterization of MHC Class Ilowprime DC for IL-12 production through IFN--dependent
Tumor Cellssignals. Others have recently shown in vitro that NK
The B cell lymphoma cell line A20 and the carcinoma cell line CT26
cells and DC can directly interact (Glas et al., 2000, and their variants were maintained in RPMI 1640 medium supple-
Gerosa et al., 2002). As anti-IFN--mAb prevented DC1 mented with 5% FCS, 2 mM glutamine, nonessential amino acids,
antibiotics, and 50 M 2-mercaptoethanol. For gene transfer, cellpriming also in vivo, it is likely that such NK cell-DC
Immunity
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GM1 antibody (Wako Chemicals, Neuß, Germany) was injected intra-
venously at days 3, 4, and 11. To stimulate NK cells in vivo, mice
received 10 nMol CpG-oligonucleotide 1668 (ref. in Egeter et al.,
2000) at days 1 and 1. All animal experiments were reproduced
one to four times. Significance was tested using the logrank test;
all results shown were between p  0.05 and p  0.005. Typical
results are shown in the figures.
Generation of T Cell Lines
CD8 T cells were prepared from spleens of transgenic mice bearing
a T cell receptor specific for influenza hemagglutinin (HA) by mag-
netic cell separation (Miltenyi Biotec, Heidelberg, Germany) using
a one-step positive selection with anti-CD8-coated microbeads (Mil-
tenyi Biotec). CD8 positive cells were then cultured with syngeneic
APC and 7.5M HA peptide (SFERFEIFPK, Biotrend, Ko¨ln, Germany)
and IL-2. After 10 days, cells were used for cytotoxicity experiments.
Ex Vivo T Cell Analysis
Four days after in vivo priming of mice with either A20 lymphoma
or A20low lymphoma, T cells were isolated from spleens by negative
selection over Biotex T cell columns (TEBU, Frankfurt, Germany) to
at least 95% purity. Isolated T cells were stimulated in vitro with
irradiated A20 tumor cells and syngeneic APC. IFN- was deter-
mined in the 24 hr culture supernatant. Part of the cells was further
expanded for 10 days with IL-2 (Chiron, Ratingen, Germany) and
again restimulated with syngeneic APC in the presence or absence
of tumor cells.
Figure 7. Rejection of MHC Class Ilow A20 Lymphoma Cells Estab- Cytotoxicity Assay
lishes T Cell Memory Responses Specific killing of A20 or A20low cells was determined using the JAM
test (Matzinger, 1991). In brief, A20 or A20low cells were loaded with(A) Four days after injection of A20low lymphoma, A20-specific T cell
3H-thymidine and pulsed with HA peptide overnight. 3H-thymidine-lines were generated. After 10 days, these T cell lines were stimu-
labeled A20 or A20low cells were incubated in 96-well plates (Greiner,lated with either APC alone or with APC and irradiated A20 cells.
Frickenhausen, Germany) with in vitro-generated HA-specific CTLNo T cell line could be established from NK cell-depleted mice.
at the indicated effector:target ratio. After 4 hr, cells were harvestedIFN- production was determined in the supernatant by ELISA. Rep-
on glass fiber filters and 3H-thymidine containing cells were deter-resentative data from three independent experiments which yielded
mined using an automatic filter counting system (TRACE96, Inotech,similar results.
Dittikon, Switzerland). The percentage of specific lysis was calcu-(B) Long-term memory induced by NK cell-mediated rejection of
lated as described (Kirberg et al., 1994).A20low variants depends on T cells. BALB/c mice were primed with
106 of MHC class Ilow A20 cells and, on day 100, re-challenged with
106 A20 wild-type tumor cells. In some of the mice, total T cells were
Detection of Cytokines
depleted 3 days prior to the second challenge with mAb MmT1. The
IFN- was quantified in cell culture supernatants by an ELISA using
data are part of the experiment shown in Figure 6A.
R4-6A2 as a capture and XMG-1.2 as a secondary mAb. All mAb
were from BD Pharmingen (Heidelberg, Germany) and recombinant
standards from R&D Systems (Wiesbaden, Germany). To quantify
lines were electroporated with the mCMV-derived genes m152 or IFN--expressing cells in vivo, spleen cells were isolated and sub-
m06 (Krmpotic et al., 1999; Ziegler et al., 1997) or with empty vector jected to an IFN- capture assay using the Miltenyi kit (Miltenyi,
cassettes using a Genepulser apparatus (Biorad, Mu¨nchen, Ger- Bergisch-Gladbach, Germany). The cells were counterstained by
many). Transfectants were selected for resistance against genet- mAb against CD11c, CD3, or DX5 and analyzed by FACS. IL-12-
icine in 96-well plates and resistant clones were tested for H-2Dd expressing cells were detected by intracellular FACS analyses.
expression using the FITC-labeled mAb HB87 (ATCC). MHC class Splenocytes were incubated for 10 hr in the presence of 1 g/ml
Ilow cells were subcloned by FACS sorting. mAb specific for H-2L, Brefeldin A (Sigma, Mu¨nchen, Germany). After staining with FITC-
I-A, CD80, CD86, CD40, and CD40L were purchased from Phar- conjugated anti-CD11c mAb, cells were fixed and permeabilized
mingen (San Diego, CA). The 6C10 mAb specifically recognizes the using the Fix and Perm Kit (Caltag, Burlingame, USA). IL-12 was
A20 Ig Id (Selmayr et al., 1999). The PE-labeled NKG2D tetramer detected by incubation with the rat anti-IL-12 mAb C17.8 followed
recognizes the NKG2D receptor ligand (Knabel et al., 2002). by phycoerythrine-labeled anti-rat IgG.
Animals and In Vivo Experiments
Female BALB/c and BALB/c nude/nude mice purchased from Bom- Determination of Cytokine mRNA
Either 106 A20 or 106 A20low cells were intravenously injected intomice (Ry, Denmark) and SCID mice grown in our animal facility were
housed under specific pathogen-free conditions. If not otherwise BALB/c mice that had received PBS or 1 mg of anti-IFN- intraperi-
toneally 4 hr before tumor cell injection. 4 hr after tumor cell injec-indicated, groups of six mice were injected intravenously with 105-
106 MHC class Ilow or wild-type tumor cells. Mice were euthanized tion, spleen cells were sorted by flow cytometry into NK cells
(DX5CD3), DC (CD11cCD19F4/80) and the corresponding NK-when showing tumor growth. Depletion of pan-T cells or CD4 or
CD8 subpopulations was performed with mAb MmT1, RmCD8-2, or and DC-depleted subpopulations. CD8 T cells were sorted from
spleens and lungs 4 days after tumor injection using anti-CD3 andRmCD4-2, respectively, as described (Mocikat et al., 1997). For NK
cell depletion, mice were intraperitoneally injected with 1 mg of IL-2 anti-CD8 antibody. After mRNA extraction, the relative levels of
IFN- and IL-12p40 mRNA were determined in the different subpop-receptor  chain-specific mAb TM-1 (Tanaka et al., 1993) 4 days
before and 0.1 mg 2 and 14 days after A20low challenge. Due to their ulations by semiquantitative RT-PCR (Biedermann et al., 2001). Re-
sults were expressed as the increase of the specific mRNA as com-lower expression density of IL-2 receptor  chain, T cells were not
eliminated by this mAb (not shown). Alternately, rabbit anti-asialo pared to noninjected control mice.
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